Primary source: Open Government Licence v3.0
The UK has committed £50 million specifically for Ebola outbreak response in the DRC, marking a rapid escalation in funding as the situation intensifies.
The accelerated funding and support are critical as the outbreak poses a risk of becoming the deadliest on record, requiring immediate action to save lives and prevent wider international spread.
Operational support will now be increased for disease surveillance, health worker assistance, and community outreach based on the new funding and response framework.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Operational support will now be increased for disease surveillance, health worker assistance, and community outreach based on the new funding and response framework.
The UK Government has announced a new funding package of over £50 million to bolster efforts against the Ebola outbreak in the DRC, raising the total UK contribution for this response to £78 million. This package aims to strengthen disease surveillance, improve health worker support, and enhance community engagement to tackle the epidemic effectively. This initiative was revealed by Africa Minister Kirsty McNeill as part of an accelerated response strategy during an urgent public health crisis.
What changed: The UK has committed £50 million specifically for Ebola outbreak response in the DRC, marking a rapid escalation in funding as the situation intensifies.
Why it matters: The accelerated funding and support are critical as the outbreak poses a risk of becoming the deadliest on record, requiring immediate action to save lives and prevent wider international spread.
Practical implication: Operational support will now be increased for disease surveillance, health worker assistance, and community outreach based on the new funding and response framework.
Published from the regulator source ingestion pipeline after PV impact triage.
Ensure that all labeling and safety information reflects the updated product name 'Prasugrel Viatris' instead of 'Prasugrel Mylan'.
The program will implement collaborative processes for the evaluation of technologies, enhancing real-world evidence integration into signal management and impacting regulatory compliance workflows.
Enhanced monitoring for products with hidden drug ingredients is required, leading to increased need for rapid reporting and investigation of adverse events associated with similar products.
Applicants must adhere to new timelines: submit a rapporteurs' allocation request 9 months prior to the intended MAA submission date, and submit their Letter of Intent at least 2 months before the MAA submission.
